|
Phase 2 randomized, placebo-controlled, double blind study of study drug in combination with Docetaxel versus Docetaxel alone for patients with Metastatic Breast Cancer. Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Phase 2 randomized, placebo-controlled, double blind study of study drug in combination with Docetaxel versus Docetaxel alone for patients with Metastatic Breast Cancer. conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Phase 2 randomized, placebo-controlled, double blind study of study drug in combination with Docetaxel versus Docetaxel alone for patients with Metastatic Breast Cancer. Clinical research trials and Phase 2 randomized, placebo-controlled, double blind study of study drug in combination with Docetaxel versus Docetaxel alone for patients with Metastatic Breast Cancer. health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Phase 2 randomized, placebo-controlled, double blind study of study drug in combination with Docetaxel versus Docetaxel alone for patients with Metastatic Breast Cancer.. Phase 2 randomized, placebo-controlled, double blind study of study drug in combination with Docetaxel versus Docetaxel alone for patients with Metastatic Breast Cancer. Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Phase 2 randomized, placebo-controlled, double blind study of study drug in combination with Docetaxel versus Docetaxel alone for patients with Metastatic Breast Cancer. clinical trial. Human subjects frequently get the finest healthcare available for their Phase 2 randomized, placebo-controlled, double blind study of study drug in combination with Docetaxel versus Docetaxel alone for patients with Metastatic Breast Cancer. condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase 2 randomized, placebo-controlled, double blind study of study drug in combination with Docetaxel versus Docetaxel alone for patients with Metastatic Breast Cancer.  Phase 2 randomized, placebo-controlled, double blind study of study drug in combination with Docetaxel versus Docetaxel alone for patients with Metastatic Breast Cancer.
Phase 2 randomized, placebo-controlled, double blind study of study drug in combination with Docetaxel versus Docetaxel alone for patients with Metastatic Breast Cancer.
For Condition: Metastatic breast cancer
Status: Recruiting
Sponsor(s): Pfizer ,
Synopsis: The primary purpose of the study is to determine the time to progression of the combination of study drug and docetaxel versus docetaxel alone in patients who have not received prior chemotherapy for metastatic breast cancer. The secondary purpose of the study is to determine the dose of study drug that can be given with docetaxel administered on an every 3 week schedule.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: - Female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease) - No prior chemotherapy for metastatic disease or adjuvent chemotherapy given within the past 12 months - No uncontrolled brain metastases - Adequate bone marrow, liver, and renal function - No evidence of preexisting uncontrolled hypertension - ECOG performance status of 0, 1, 2 - At least one target lesions, as defined by RECIST - Adults at least 18 years of age - Negative serum pregnancy test for patients of child bearing potential - Life expectancy at least 12 weeks - Written informed consent
Total Enrollment: 186
Location and Contact Information:
Pfizer Investigational Site *Recruiting*
Tucson, Arizona, 85719-4824
United States
Recruiting
Pfizer Investigational Site *Recruiting*
San Francisco, California, 94115
United States
Recruiting
Additional Information:
Study ID Numbers: A4061010;
Study Start Date: November 2003
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00076024
Other Metastatic Breast Cancer Studies:
1. Novel Epothilone (BMS-247550) in Patients with Metastatic Breast Cancer (MBC)
2. Standard Whole Brain Radiation Therapy with Supplemental Oxygen, with or without Concurrent RSR13 (efaproxiral), in Women with Brain Metastases from Breast Cancer
3. An Investigational Drug versus Capecitabine in Male or Female Patients with Advanced Breast Cancer
4. GW572016 For Treatment Of Refractory Metastatic Breast Cancer
5. Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer
Related Studies:
Other Metastatic breast cancer Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
Phase 2 randomized, placebo-controlled, double blind study of study drug in combination with Docetaxel versus Docetaxel alone for patients with Metastatic Breast Cancer.
|
|
|
|
|
|
|
|
